Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ecallantide for Reducing Surgical Blood Loss in CABG (CONSERV-1)
NCT00816023Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Mar 2009
- Primary completion
- Dec 2009
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
A Phase 2 trial of ecallantide, sponsored by Merck & Co.. Started Mar 2009; status: completed.
02
Drugs
ecallantide
Beyond the preview
Go deeper on NCT00816023.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00816023.